Literature DB >> 9002545

The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms.

G Wolf1, F N Ziyadeh.   

Abstract

Several systemic or intrarenal networks of cytokines and growth factors can be modulated by the diabetic state. We summarize the status of the renin-angiotensin system in diabetes mellitus and review the evidence of its involvement in the pathogenesis of diabetic nephropathy. Particular emphasis is placed on the nonhemodynamic properties of this vasoactive agent as both a renal growth factor and a profibrogenic peptide. Antagonizing the effects of angiotensin II with converting enzyme inhibitors is an established protective strategy in the management of diabetic nephropathy even in the absence of systemic hypertension. This and other indirect evidence from experimental animal studies suggest that the intrarenal concentration of angiotensin II may be increased as a result of increased synthesis and despite enhanced breakdown, that this peptide participates in the progression of diabetic nephropathy. However, down-regulation of angiotensin type 1 (AT1)-receptors is one of the abnormalities of both tubules and glomeruli in diabetic renal disease. A heightened bioactivation of the intrarenal angiotensin II system is therefore likely but not certain. Studies in cultured proximal tubular and glomerular mesangial cells have disclosed striking similarities between the effects of high glucose-containing medium and of treatment with angiotensin II on the growth properties and the induction of cytokines in these cells. There may also exist additive effects of angiotensin II and high glucose on signal-transduction pathways, such as activation of protein kinase C, although the contractile response to angiotensin II may be blunted by high glucose in mesangial cells. An important downstream mediator of the effects of both angiotensin II and high glucose is the activation of transforming growth factor-beta that can mediate at least some of the hypertrophic and profibrotic effects of either angiotensin II or high glucose in the diabetic kidney.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9002545     DOI: 10.1016/s0272-6386(97)90023-8

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  31 in total

1.  Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells.

Authors:  J S Huang; J Y Guh; W C Hung; M L Yang; Y H Lai; H C Chen; L Y Chuang
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

2.  Epigenetic histone methylation modulates fibrotic gene expression.

Authors:  Guangdong Sun; Marpadga A Reddy; Hang Yuan; Linda Lanting; Mitsuo Kato; Rama Natarajan
Journal:  J Am Soc Nephrol       Date:  2010-10-07       Impact factor: 10.121

3.  Thrombospondin 1 and Its Diverse Roles as a Regulator of Extracellular Matrix in Fibrotic Disease.

Authors:  Joanne E Murphy-Ullrich
Journal:  J Histochem Cytochem       Date:  2019-05-22       Impact factor: 2.479

Review 4.  Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update.

Authors:  K O Alsaad; A M Herzenberg
Journal:  J Clin Pathol       Date:  2007-01       Impact factor: 3.411

Review 5.  TGF-beta: a crucial component of the pathogenesis of diabetic nephropathy.

Authors:  S Goldfarb; F N Ziyadeh
Journal:  Trans Am Clin Climatol Assoc       Date:  2001

6.  Store-Operated Ca2+ Channels in Mesangial Cells Inhibit Matrix Protein Expression.

Authors:  Peiwen Wu; Yanxia Wang; Mark E Davis; Jonathan E Zuckerman; Sarika Chaudhari; Malcolm Begg; Rong Ma
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

Review 7.  Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research.

Authors:  Benjamin M Leon; Thomas M Maddox
Journal:  World J Diabetes       Date:  2015-10-10

8.  Changes of urinary angiotensinogen concentration and its association with urinary proteins in diabetic rats.

Authors:  Zhen Zhuang; Qiong Bai; A Lata; Yaoxian Liang; Danxia Zheng; Yue Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 9.  Angiotensin receptor blockers in diabetic nephropathy.

Authors:  D A Price; N K Hollenberg
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

10.  Products of 12/15-lipoxygenase upregulate the angiotensin II receptor.

Authors:  Zhong-Gao Xu; Hang Yuan; Linda Lanting; Shu-Lian Li; Mei Wang; Narkunaraja Shanmugam; Mitsuo Kato; Sharon G Adler; Marpadga A Reddy; Rama Natarajan
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.